It been quite a while since we touched base with INMED PHARMACEUTIC (OTCMKTS:IMLFF) here on Street Register- since this spring, in fact. Just for a refresher, the company primarily bills itself as a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, and it’s this cannabinoid research that really draws us to this stock.
We are huge proponents of the legal and medical marijuana industries, which have about as much upside potential as any other market sector out there, if not more. One of the main reasons for this is the undeniable medical properties of not just the plant itself, but the various complex compounds found in and/or derived from it.
We mentioned in the title that INMED PHARMACEUTIC (OTCMKTS:IMLFF) has some intriguing pre-clinical cannabinoid research underway, and it is genuinely unique to any other we’ve read about, being concerned with a topical, ocular application. The company recently reported some favorable progress with those trials. Results from a study co-sponsored by InMed (Dr. Sazzad Hossain, Chief Scientific Officer) and the University of British Columbia (laboratories of Profs. Ujendra Kumar and Vikramaditya Yadav) were promising.
The InMed-UBC study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye, resulting in enhanced drug uptake via the cornea and lens. This study further validates the Company’s capacity to conduct a wide spectrum of drug development activities, including biosynthesis of a cannabinoid using a novel E. coli-based system, packaging the cannabinoid as a nanoparticle, formulation of a cannabinoid drug candidate into a tissue-specific delivery vehicle, and confirmation of drug delivery and diffusion into a target tissue.
Typical ocular formulations, such as eye drops, are washed away almost immediately upon administration due to blinking. In this study, InMed’s proprietary hydrogel delivery method offers unique rheological characteristics permitting it to form a thin, uniform coating, a gel-like ‘lens’, over the cornea through blinking of the eyelid. This ‘lens’ holds the drug in place and allows for trans-corneal absorption of the drug, which can then diffuse within the eye to the retina. Total drug delivered using this hydrogel nanoparticle formulation was three-times higher than the control formulation.
“Importantly, this study offers further validation of InMed’s capabilities in moving the science of cannabinoid pharmaceuticals forward”, said Eric A. Adams, President & CEO of InMed. “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned scientific team and collaborators demonstrates our depth of know-how and supports our trajectory to becoming an industry leader.”
Further disclosure of study data is embargoed pending publication in a peer-reviewed journal. (Source: PR Newswire)
The company will be moving forward on these key studies with the help of a new scientific Dr. Mauro Maccarrone is Professor and Chair of Biochemistry and Molecular Biology at Campus Bio-Medico, University of Rome. He also serves as Director of the Laboratory of Lipid Neurochemistry of the European Center for Brain Research-IRCCS Santa Lucia Foundation in Rome. Prof. Maccarrone served as the President of the International Cannabinoid Research Society and was the recipient of their 2016 Mechoulam Award. (Source: PRNewswire)
We’re going to want to stay hot on trail of ILMFF’s important ocular drug delivery system for cannabinoids, and follow the story every step of the way. Keep it locked to Street Register for updates, and we’ll deliver those important developments on IMLFF to you as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!
Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in IMLFF stock, short or long.